Literature DB >> 11687140

Management of faecal incontinence and constipation in adults with central neurological diseases.

P H Wiesel1, C Norton, M Brazzelli.   

Abstract

BACKGROUND: People with neurological disease have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine dividing line between the two conditions, with any management intended to ameliorate, one risking precipitating the other. Bowel problems are observed to be the cause of much anxiety and may reduce quality of life in these people. Current bowel management is largely empirical with a limited research base.
OBJECTIVES: To determine the effects of management strategies for faecal incontinence and constipation in people with neurological diseases affecting the central nervous system. SEARCH STRATEGY: We searched the Cochrane Incontinence Group Trials Register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE and all reference lists of relevant articles. Date of the most recent searches: May 2000. SELECTION CRITERIA: All randomised or quasi-randomised trials evaluating any types of conservative, or surgical measure for the management of faecal incontinence and constipation in people with neurological diseases were selected. Specific therapies for the treatment of neurological diseases that indirectly affect bowel dysfunction have also been considered. DATA COLLECTION AND ANALYSIS: All three reviewers assessed the methodological quality of eligible trials and two reviewers independently extracted data from included trials using a range of pre-specified outcome measures. MAIN
RESULTS: Only seven trials were identified by the search strategy and all were small and of poor quality. Oral medications for constipation were the subject of four trials. Cisapride does not seem to have clinically useful effects in people with spinal cord injuries (two trials). Psyllium was associated with increased stool frequency in people with Parkinson's disease but not altered colonic transit time (one trial). Some rectal preparations to initiate defecation produced faster results than others (one trial). Different time schedules for administration of rectal medication may produce different bowel responses (one trial). Mechanical evacuation may be more effective than oral or rectal medication (one trial). The clinical significance of any of these results is difficult to interpret. REVIEWER'S
CONCLUSIONS: It is not possible to draw any recommendation for bowel care in people with neurological diseases from the trials included in this review. Bowel management for these people must remain empirical until well-designed controlled trials with adequate numbers and clinically relevant outcome measures become available.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687140     DOI: 10.1002/14651858.CD002115

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  3 in total

Review 1.  The treatment of chronic constipation in elderly people: an update.

Authors:  Wanda Bosshard; Rebecca Dreher; Jean-François Schnegg; Christophe J Büla
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 2.  Outcome measures in spinal cord injury: recent assessments and recommendations for future directions.

Authors:  M S Alexander; K D Anderson; F Biering-Sorensen; A R Blight; R Brannon; T N Bryce; G Creasey; A Catz; A Curt; W Donovan; J Ditunno; P Ellaway; N B Finnerup; D E Graves; B A Haynes; A W Heinemann; A B Jackson; M V Johnston; C Z Kalpakjian; N Kleitman; A Krassioukov; K Krogh; D Lammertse; S Magasi; M J Mulcahey; B Schurch; A Sherwood; J D Steeves; S Stiens; D S Tulsky; H J A van Hedel; G Whiteneck
Journal:  Spinal Cord       Date:  2009-04-21       Impact factor: 2.772

3.  Traditional East Asian herbal medicines for the treatment of poststroke constipation: A protocol for systematic review and meta analysis.

Authors:  Chul Jin; Bo-Hyoung Jang; Jin Pyeong Jeon; Ye-Seul Lee; Seung-Bo Yang; Seungwon Kwon
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.